Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11018767 | 1.00 | NR1I2 (0.51) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL28750606 | 1.00 | NR1I2 (0.51) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL7648738 | 1.00 | NR1I2 (0.51) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL7649259 | 0.96 | NR1I2 (0.49) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL10481897 | 0.91 | NR1I2 (0.45) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL27976821 | 0.91 | NR1I2 (0.45) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL18660101 | 0.90 | NR1I2 (0.58) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL3289894 | 0.88 | HRH3 (0.45) | NR1I2HTTHRH3SLC2A1CHRNA7 | |
| SCHEMBL25334695 | 0.84 | NR1I2 (0.47) | NR1I2HTTHRH3SLC2A1L3MBTL1 | |
| SCHEMBL10713006 | 0.84 | NR1I2 (0.47) | NR1I2HTTHRH3SLC2A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379484-A2 | PROCESS FOR THE MONO-ALKYLATION OF MONOCYCLIC AROMATIC HYDROCARBON | Akzo Nobel Surface Chemistry Aktiebolag (SE) | 2004-01-14 | — | — | EP | disclosed |
| US-20020198420-A1 | Mono-alkylation process for the preparation of anionic surfactants | CROMPTON CORPORATION. | 2002-12-26 | — | — | US | disclosed |
| WO-2002074720-A2 | PROCESS FOR THE MONO-ALKYLATION OF MONOCYCLIC AROMATIC HYDROCARBON | AKZO NOBEL SURFACE CHEMISTRY A.B. (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198420-A1 | Mono-alkylation process for the preparation of anionic surfactants | MGMT, ALK, PCNA | NR1I2 3037/4885HTT 1066/4885HRH3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.